123572-65-6

Basic information

• Product Name: 4-Fluoro-1-nitro-2-(trifluoromethoxy)benzene
• Synonyms: 4-Fluoro-1-nitro-2-(trifluoromethoxy)benzene
• CAS NO: 123572-65-6
• Molecular Weight: 225.099
• Mol File: 123572-65-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-Fluoro-1-nitro-2-(trifluoromethoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Fluoro-1-nitro-2-(trifluoromethoxy)benzene(123572-65-6)
• EPA Substance Registry System: 4-Fluoro-1-nitro-2-(trifluoromethoxy)benzene(123572-65-6)

Safety Data

• Hazardous Substances Data: 123572-65-6(Hazardous Substances Data)

Upstream product

• 1077-01-6 meta-fluoro(trifluoromethoxy)benzene 

Downstream Products

• 1159795-41-1 4-methyl-1-(2-nitro-5-trifluoromethoxy-phenyl)-1H-imidazole 
• 1383810-90-9 C₁₁H₁₃F₃N₂O₂ 
• 1246532-06-8 N₆-cyclohexyl-N₂-[4-(morpholin-4-yl)-2-(trifluoromethoxy)phenyl]-9H-purine-2,6-diamine 
• 1395172-33-4 C₁₁H₁₁F₃N₂O₄ 
• 123572-66-7 4-fluoro-2-(trifluoromethoxy)benzenamine 

Relevant articles and documents

2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS

The present invention relates to 2,4-diaminopyrimidines and pharmaceutically acceptable salts thereof, purification methods for the same, pharmaceutical compositions containing them, methods of obtaining and using them for the treatment of disease states,

EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF

A 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivative as represented by formula (I), and a preparation and application thereof as an EGFR inhibitor. The compound has activity of inhibiting the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, may be used to treat diseases mediated alone or in part by EGFR mutant activity, and has a wide application in drugs preventing and treating cancers, particularly non-small cell lung cancer.

1-PHENYLPYRROLE COMPOUNDS

The present invention comprises a compound for the prevention and/or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein R1 represents a C1 -C3 alkyl group; R2 represents a hydroxy -C1 -C4 alkyl group and the like; R3 represents a halogeno group, a halogeno-C1 -C3 alkyl group and the like; R4 represents a hydrogen atom, a halogeno group and the like,- R5 represents a sulfamoyl group or a C1-C3 alkylsulf onyl group; R6 represents a hydrogen atom, a halogeno group and the like] or an N-oxide, atropisomer of the foregoing, or pharmaceutically acceptable salt of the foregoing.